To measure the effect of Ivermectin (sub-cutaneous) with or without zinc in treating the COVID-19 patients to clear viral load of SARS-CoV-2 along with reduction in severity of symptoms and length of hospitalization of patients with COVID-19.

This is a parallel assigned, randomized, controlled, multi-armed, investigator Initiated interventional study is designed to demonstrate efficacy to lower the viral load of COVID-19 and to demonstrate the antiviral effects of subcutaneous Ivermectin with or without zinc in mild to moderate symptomatic patients who consent to randomization following a new diagnosis in Pakistan with COVID-19 (PCR positive). Investigators will follow up with participants daily and PCR will be done on alternate days in BSL-3 lab. Dose will only be repeated if test remained positive..

Inclusion Criteria:

• Nasopharyngeal RT-PCR positive SARS-CoV-2 patient with mild to moderate disease
• Age 18 and above
• BMI 18-28 kg/m

Exclusion Criteria:

• Allergy to any drug
• Co-morbidities: any pre-existing cardiac disease, pulmonary disease
• Arrhythmias
• Pregnancy
• RT-PCR performed >3 days prior to enrollment

Empty capsule will sub-cutaneous injection of ivermectin will be used